The Metabolic Syndrome, Thiazolidinediones, and Implications for Intersection of Chronic and Inflammatory Disease

Overview

Journal Mol Metab

Specialty Cell Biology

Date 2021 Dec 5

PMID 34863942

Citations 13

Authors

Jerry R Colca

Philipp E Scherer

Affiliations

Soon will be listed here.

Abstract

Background: Chronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself.

Scope Of Review: Further study of the first generation "insulin sensitizer" pioglitazone and molecules based on its structure suggests that is possible to decouple body weight from the metabolic dysfunction that drives adverse outcomes. The growing understanding of the mechanism of action of these agents together with advances in the pathophysiology of chronic metabolic disease offers a new approach to treat chronic conditions, such as type 2 diabetes, fatty liver disease, and their common organ and vascular sequelae.

Major Conclusions: We hypothesize that treating adipocyte dysfunction with new insulin sensitizers might significantly impact the interface of infectious disease and chronic metabolic disease.

Citing Articles

Pioglitazone improves learning and memory in a rat model of cholinergic dysfunction induced by scopolamine, the roles of oxidative stress and neuroinflammation.

Rajabian A, Kioumarsi Darbandi Z, Aliyari M, Saberi R, Amirahmadi S, Amini H Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39960561 DOI: 10.1007/s00210-025-03895-5.

Insulin resistance has closer correlation with the occurrence of metabolic dysfunction associated steatotic liver disease diagnosed by liver biopsy.

Cao W, Jiang T, Deng W, Wang S, Li X, Zhang Z Front Med (Lausanne). 2024; 11:1384927.

PMID: 39618812 PMC: 11604430. DOI: 10.3389/fmed.2024.1384927.

Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.

Lin L, Pan X, Feng Y, Yang J Ther Adv Endocrinol Metab. 2024; 15:20420188241252309.

PMID: 39071115 PMC: 11273817. DOI: 10.1177/20420188241252309.

The cellular and molecular targets of natural products against metabolic disorders: a translational approach to reach the bedside.

Shen X, Yang H, Yang Y, Zhu X, Sun Q MedComm (2020). 2024; 5(8):e664.

PMID: 39049964 PMC: 11266934. DOI: 10.1002/mco2.664.

Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.

Rohm T, Castellani Gomes Dos Reis F, Isaac R, Murphy C, Cunha E Rocha K, Bandyopadhyay G Nat Metab. 2024; 6(5):880-898.

PMID: 38605183 PMC: 11430498. DOI: 10.1038/s42255-024-01023-w.

References

Fadini G, Morieri M, Longato E, Avogaro A . Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 43(6):867-869. PMC: 7103097. DOI: 10.1007/s40618-020-01236-2. View

Huang S, Jiang L, Cheon I, Sun J . Targeting Peroxisome Proliferator-Activated Receptor-Gamma Decreases Host Mortality After Influenza Infection in Obese Mice. Viral Immunol. 2019; 32(4):161-169. PMC: 6534095. DOI: 10.1089/vim.2019.0016. View

Malodobra-Mazur M, Cierzniak A, Kaliszewski K, Dobosz T . Hypermethylation as the First Epigenetic Modification in Newly Onset Insulin Resistance in Human Adipocytes. Genes (Basel). 2021; 12(6). PMC: 8228025. DOI: 10.3390/genes12060889. View

Colca J, Tanis S, McDonald W, Kletzien R . Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin Investig Drugs. 2013; 23(1):1-7. DOI: 10.1517/13543784.2013.839659. View

Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti G . Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019; 20(9). PMC: 6539070. DOI: 10.3390/ijms20092358. View

Chia C, Egan J . Incretins in obesity and diabetes. Ann N Y Acad Sci. 2019; 1461(1):104-126. PMC: 10131087. DOI: 10.1111/nyas.14211. View

Kotronen A, Vehkavaara S, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H . Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007; 293(6):E1709-15. DOI: 10.1152/ajpendo.00444.2007. View

Matsumura Y, Nakaki R, Inagaki T, Yoshida A, Kano Y, Kimura H . H3K4/H3K9me3 Bivalent Chromatin Domains Targeted by Lineage-Specific DNA Methylation Pauses Adipocyte Differentiation. Mol Cell. 2015; 60(4):584-96. DOI: 10.1016/j.molcel.2015.10.025. View

Musso G, Cassader M, Paschetta E, Gambino R . Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177(5):633-640. PMC: 5470366. DOI: 10.1001/jamainternmed.2016.9607. View

10.

McCommis K, Hodges W, Brunt E, Nalbantoglu I, McDonald W, Holley C . Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2016; 65(5):1543-1556. PMC: 5397348. DOI: 10.1002/hep.29025. View

11.

Kozawa J, Shimomura I . Ectopic Fat Accumulation in Pancreas and Heart. J Clin Med. 2021; 10(6). PMC: 8004936. DOI: 10.3390/jcm10061326. View

12.

Colca J . The TZD insulin sensitizer clue provides a new route into diabetes drug discovery. Expert Opin Drug Discov. 2015; 10(12):1259-70. DOI: 10.1517/17460441.2015.1100164. View

13.

Malodobra-Mazur M, Cierzniak A, Myszczyszyn A, Kaliszewski K, Dobosz T . Histone modifications influence the insulin-signaling genes and are related to insulin resistance in human adipocytes. Int J Biochem Cell Biol. 2021; 137:106031. DOI: 10.1016/j.biocel.2021.106031. View

14.

Sarafidis P, Nilsson P . The metabolic syndrome: a glance at its history. J Hypertens. 2006; 24(4):621-6. DOI: 10.1097/01.hjh.0000217840.26971.b6. View

15.

Yadav R, Aggarwal S, Singh A . SARS-CoV-2-host dynamics: Increased risk of adverse outcomes of COVID-19 in obesity. Diabetes Metab Syndr. 2020; 14(5):1355-1360. PMC: 7372253. DOI: 10.1016/j.dsx.2020.07.030. View

16.

DeFronzo R, Inzucchi S, Abdul-Ghani M, Nissen S . Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16(2):133-143. DOI: 10.1177/1479164118825376. View

17.

Pilla S, Segal J, Alexander G, Boyd C, Maruthur N . Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults. J Am Geriatr Soc. 2019; 67(5):1066-1073. PMC: 6488408. DOI: 10.1111/jgs.15790. View

18.

Tedesco S, Ciciliot S, Menegazzo L, DAnna M, Scattolini V, Cappellari R . Pharmacologic PPAR-γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes. Diabetes. 2020; 69(7):1562-1572. DOI: 10.2337/db19-0640. View

19.

Colca J, Kletzien R . What has prevented the expansion of insulin sensitisers?. Expert Opin Investig Drugs. 2006; 15(3):205-10. DOI: 10.1517/13543784.15.3.205. View

20.

Bardova K, Funda J, Pohl R, cajka T, Hensler M, Kuda O . Additive Effects of Omega-3 Fatty Acids and Thiazolidinediones in Mice Fed a High-Fat Diet: Triacylglycerol/Fatty Acid Cycling in Adipose Tissue. Nutrients. 2020; 12(12). PMC: 7761951. DOI: 10.3390/nu12123737. View